Press Releases
- Cerimon to Conduct a Proof of Concept Study for Basiliximab for Noninfectious Uveitis, a Potentially Sight-Threatening Inflammation of the Eye
March 10, 2008
- Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate Its Diclofenac Patch for Mild to Moderate Pain
January 16, 2008
- Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
January 4, 2008
- Cerimon Pharmaceuticals to Present at the 2007 BIO Investor Forum
October 5, 2007 - Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch
October 2, 2007 - Cerimon Pharmaceuticals Initiates ARREST UC-1, a Global Phase 2b Study of Basiliximab in Patients with Steroid-Refractory Ulcerative Colitis
April 4, 2007 - Cerimon Pharmaceuticals Names Daniel Levitt, M.D., Ph.D. Executive Vice President of Research and Development
January 8, 2007 - Cerimon Pharmaceuticals Names Ayse Kocak Vice President of Marketing
December 5, 2006 - Cerimon Pharmaceuticals Announces Creation of Scientific Advisory Board
November 3, 2006
- Cerimon Pharmaceuticals Names James Welch as Chief Financial Officer
June 6, 2006
- Cerimon Pharmaceuticals Licenses Exclusive Worldwide Rights to Simulect® for the Treatment of Inflammatory Bowel Disease
February 21, 2006
- Cerimon Pharmaceuticals Raises $70 Million in Series A Financing
October 26, 2005
- Cerimon Pharmaceuticals Acquires First Clinical-Stage Product in Inflammation and Pain Program
October 26, 2005